Permanently Implanted Prostatic Devices for Benign Prostatic Hyperplasia
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Massachusetts Policy 252 alerts
Get alerted when Policy 252 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of permanently implanted prostatic stent devices used to treat lower urinary tract symptoms due to benign prostatic hyperplasia for eligible Commercial and Medicare HMO/PPO members, including investigational status, authorization requirements, and applicable procedure codes.
A new medical policy establishes permanently implanted prostatic stent devices as investigational for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.